Johanna C. Bendell, MD - How I Think, How I Treat—Personal Insights on Current Practices and Evolving Standards of Care in Pancreatic Cancer: Expert Perspectives on Implementing State-of-the-Art Care in the Clinic - a podcast by PVI, PeerView Institute for Medical Education
from 2020-03-27T18:00
Go online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solutions are on the horizon for unmet clinical needs in locally advanced and metastatic settings? Through collaboration with Let’s Win, an affiliate of the Lustgarten Foundation, this PeerView Live on-demand activity answers these key questions and others with a “How I Think, How I Treat” educational design, providing a personal look at the way experts consider important new and emerging data while navigating the current pancreatic cancer treatment landscape to enhance patient care and outcomes. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence on use of novel chemotherapy platforms, immunotherapy, PARP inhibitors, stromal-targeting agents, and tumor treating field therapy, among others, for pancreatic cancer, Examine the emerging role of PARP inhibitors in frontline, maintenance setting for patients with BRCA-mutant pancreatic cancer, Summarize ongoing clinical trials investigating innovative therapies, including immunotherapy, tumor treating fields, combinations with chemotherapy platforms, among others, for patients with pancreatic cancer, Recommend optimal treatment plans, including the enrollment of clinical trials, across multiple lines of therapy for patients with advanced pancreatic cancer based on validated evidence, guideline recommendations, and disease- and patient-specific factors
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education